IntraBio is a biopharmaceutical company founded in 2015 to discover, develop, and commercialize novel treatments for rare and neurodegenerative diseases with high unmet medical needs.
Its clinical programs leverage the pioneer work of its founding scientific researchers from the University of Oxford and University of Munich, preeminent experts in lysosomal biology and neurology. IntraBio’s management team and scientific advisory board have vast commercial and regulatory experience in all stages of drug product development, including small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe.Our Scientists
IntraBio's leading drug candidate is currently being used in 17 ongoing clinical trials (observational and a Phase II/III) for 17 different indications. It has been granted Orphan Medicinal Product Designation by the European Medicines Agency (EMA) for the treatment of Niemann-Pick Diseases and GM2 Gangliodosis.
IntraBio has 4 additional small-molecule drug candidates that have broad applicability for rare and common neurological disorders, genetic, and inflammatory diseases.Our Publications
IntraBio is in the process of applying for multi-national, randomized, placebo-controlled clinical trials to evaluate the safety and efficacy of its leading compound as a therapeutic intervention in patients with Niemann-Pick Disease Type-C, Tay-Sachs Disease, and specific subtypes of Cerebellar Ataxia. Details of the clinical trials, including inclusion criteria and enrolment procedures, can be found under clinical programs.Clinical Developments